It was found that Lorviqua' a third-generation non-small cell lung cancer treatment that inhibits ALK (anaplastic lymphoma kinase), failed just before being listed. The HIRA announced the establishment of a standard next month, but the NHIS negotiations were not completed, leading to the deletion again. According to the industry on the 19th, Lorviqua passed the HIRA Pharmaceutical Benefit Evaluation Committee in April and has since been negotiating drug prices with the NHIS. As the committee judged that there is an appropriate benefit for the treatment of adult patients with ALK-positive progressive non-small cell lung cancer, the industry believes that it would not be unreasonable to pass if the pharmaceutical comp